gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · DERMHealthcarePharmaceuticals

Journey Medical Corporation Common Stock (DERM)

$4.73+1.94%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$4.80▼ 43.66% in range
Nov 3, 2025Low $4.39 · High $9.26Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Journey Medical closed at $4.73 on Nov 4, up 1.94%, 48.9% below its 52-week closing high. Volume of 118.4K shares was 0.57× its 20-day average (below normal).

Split-adjusted performance: -23.2% over one month, -9.2% over six months, -44.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $17.84M, up 18.9% from a year earlier, with a net margin of -1.7%.

Short interest was 3.0M shares at the Oct 15 settlement, down 2.2% from the prior report (24.8% of float, 16.6 days to cover).

Market cap$133.5M28.2M shares
Revenue · quarter$17.8M+18.9% YoY
Diluted EPS$-0.01—
P/E · TTM—P/S 2.0×
Net margin-1.7%Gross 65.6%
Dividend yieldNone
52-week range4.39 – 9.26−48.9% from high
Volume118.4K0.57× 20-day avg
Volatility · 60d64.5%Annualised
Short % of float24.8%16.6 days to cover
Net cash-$245.0KCash $25.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.6%1M −23.2%3M −27.6%6M −9.2%YTD −38.7%1Y −44.5%3Y +47.8%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum65
Revenue growth66
Net margin67
Value (low P/E)—
Size44

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short3.0M−2.2% vs prior
Days to cover16.6Settled Oct 15
% of float24.8%
Short vol. 10d44.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
DERMJourney Medical$4.73+1.94%−9.2%+18.9%−1.7%—$133.5M
SPRBSpruce Biosciences$46.61+8.88%−19.5%———$134.0MCompare
PYXSPyxis Oncology$1.66+1.22%−27.8%−100.0%——$138.5MCompare
YARWYarrow Bioscience$14.91−18.84%————$125.8MCompare
FHTXFoghorn Therapeutics$2.10−1.41%−55.1%+112.7%−44.7%—$124.7MCompare
NKTXNkarta$1.73+13.07%−47.9%———$123.9MCompare
CUECue Biopharma$19.84−4.89%−41.6%+166.7%−1943.2%—$144.1MCompare
NERVMinerva Neurosciences$2.57+9.36%−58.7%———$122.7MCompare
MGNXMacroGenics$2.31−0.86%−23.3%+378.0%59.4%—$147.1MCompare

News about Journey Medical

All news →
Will Journey Medical Corporation (DERM) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research · 18h ago▼ NegativeAre Options Traders Betting on a Big Move in Journey Medical Stock?Zacks Investment Research · Sep 21, 2026▼ NegativePapulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's LaboratoriesGlobeNewswire Inc. · Aug 31, 2026▲ PositiveINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERMGlobeNewswire Inc. · Apr 28, 2026▼ Negative

Quick answers

What does Journey Medical do?
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions.
What is DERM's market cap?
$133.50M, based on the Nov 4 close of $4.73.
Does Journey Medical pay a dividend?
No regular cash dividend has been paid in the last year.
How much of DERM is sold short?
3.0M shares, 24.8% of float, as of Oct 15, 2026.
What sector is DERM in?
Healthcare, in the Pharmaceuticals industry.

About Journey Medical

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

HQ: Scottsdale, AZ58 employeesListed Nov 12, 2021jmcderm.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology